A
Power Law company profile
Ambrx
Biotech & Life Sciences · San Diego, United States · Founded 2003 · IPO 2021 Unicorn
Valuation
$1.55B
Market cap · 2026
Revenue
$7.4M
Latest reported FY
Global footprint
Where Ambrx has talent and traffic
Web traffic by country
1.7K
monthly visits
across markets
across markets
🇺🇸 United States41.2%
🇹🇷 Turkey29.4%
🇮🇳 India29.4%
Patent intelligence
$129M patent portfolio · 45 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$129M
8.3% of market cap · 6.7× the top peer Vaxcyte ($19M)
45 active patent families
Where Ambrx innovates
Amino acidMolecular biologyAntiendomysial antibodiesCell biologyBiochemistry
Below peer median on Legal, Strategic
Quality vs same-sector peers
Ambrx on the five Patsnap quality dimensions
Ambrx in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Ambrx concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Ambrx and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Ambrx on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.